205 related articles for article (PubMed ID: 24688783)
1. Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer.
Palmer JD; Zaorsky NG; Witek M; Lu B
J Thorac Dis; 2014 Apr; 6(4):387-98. PubMed ID: 24688783
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
3. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
Saito M; Suzuki H; Kono K; Takenoshita S; Kohno T
Surg Today; 2018 Jan; 48(1):1-8. PubMed ID: 28280984
[TBL] [Abstract][Full Text] [Related]
4. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
5. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
6. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
7. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for lung cancer: present and future.
Aggarwal C
Ann Palliat Med; 2014 Jul; 3(3):229-35. PubMed ID: 25841697
[TBL] [Abstract][Full Text] [Related]
9. Targetable "driver" mutations in non small cell lung cancer.
Vijayalakshmi R; Krishnamurthy A
Indian J Surg Oncol; 2011 Sep; 2(3):178-88. PubMed ID: 22942608
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomic biomarkers for personalized cancer treatment.
Rodríguez-Antona C; Taron M
J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets.
Veldore VH; Patil S; Satheesh CT; Shashidhara HP; Tejaswi R; Prabhudesai SA; Krishnamoorthy N; Hazarika D; Naik R; Rao RM; Ajai Kumar BS
Indian J Cancer; 2015; 52(2):243-8. PubMed ID: 26853422
[TBL] [Abstract][Full Text] [Related]
12. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
[TBL] [Abstract][Full Text] [Related]
13. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapy for Non-Small Cell Lung Cancer.
Noor ZS; Cummings AL; Johnson MM; Spiegel ML; Goldman JW
Semin Respir Crit Care Med; 2020 Jun; 41(3):409-434. PubMed ID: 32450595
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
Dietz S; Christopoulos P; Yuan Z; Angeles AK; Gu L; Volckmar AL; Ogrodnik SJ; Janke F; Fratte CD; Zemojtel T; Schneider MA; Kazdal D; Endris V; Meister M; Muley T; Cecchin E; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
EBioMedicine; 2020 Dec; 62():103103. PubMed ID: 33161228
[TBL] [Abstract][Full Text] [Related]
16. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic driver mutations in lung cancer.
Luo SY; Lam DC
Transl Respir Med; 2013 Dec; 1(1):6. PubMed ID: 27234388
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers in precision medicine and drug development against lung cancer.
Fang B; Mehran RJ; Heymach JV; Swisher SG
Chin J Cancer; 2015 Jul; 34(7):295-309. PubMed ID: 26134262
[TBL] [Abstract][Full Text] [Related]
19. Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.
Sweis RF; Thomas S; Bank B; Fishkin P; Mooney C; Salgia R
Cureus; 2016 Feb; 8(2):e513. PubMed ID: 27026837
[TBL] [Abstract][Full Text] [Related]
20. EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.
de Mello RA; Madureira P; Carvalho LS; Araújo A; O'Brien M; Popat S
Pharmacogenomics; 2013 Nov; 14(14):1765-77. PubMed ID: 24192124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]